

**WE CLAIM:**

1. Compounds having the structure of Formula I:


2

3

4

5

6

**Formula - I**

7 and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates,  
 8 esters, enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein

9 Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms, the aryl or  
 10 heteroaryl rings may be unsubstituted or substituted by one to three substituents  
 11 independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano,  
 12 hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted  
 13 amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino, amino carbonyl, or N-lower alkyl (C<sub>1</sub>-  
 14 C<sub>4</sub>) or -aryl amino carbonyl;  
 15

16 R<sub>1</sub> represents a hydrogen, hydroxy, hydroxy methyl, substituted or unsubstituted  
 17 amino, alkoxy, carbamoyl or halogen;

18 R<sub>2</sub> represents alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl ring, a C<sub>3</sub>-C<sub>7</sub> cyclo alkenyl ring, an aryl,  
 19 heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl,  
 20 heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three  
 21 substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-  
 22 C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>),  
 23 lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl  
 24 amino, amino carbonyl, or N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino carbonyl;

25 W represents (CH<sub>2</sub>)<sub>p</sub>, wherein p represents 0 to 1;


26 X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen  
 27 or (C<sub>1</sub>-6) alkyl;

28 Y represents CHR<sub>5</sub>CO or (CH<sub>2</sub>)<sub>q</sub> wherein R<sub>5</sub> represents hydrogen or methyl and q  
 29 represents 0 to 4;


30 Z represents oxygen, sulphur, or NR<sub>10</sub>, wherein R<sub>10</sub> represents hydrogen or C<sub>1</sub>-  
 31 alkyl;

32        Q represents  $-(CH_2)_n-$ , wherein n represents 0 to 4,  $CHR_8$ , wherein  $R_8$  represents  
 33        H, OH,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkenyl, or  $C_{1-6}$  alkoxy, or Q represents  $CH_2CHR_9$ , wherein  
 34         $R_9$  represents H, OH, lower alkyl ( $C_1-C_4$ ) or lower alkoxy ( $C_1-C_4$ ); and  
 35         $R_6$  and  $R_7$  are independently selected from H,  $CH_3$ ,  $COOH$ ,  $CONH_2$ ,  $NH_2$ , and  
 36         $CH_2NH_2$ .

1        2. The compounds according to claim 1 having the structure of Formula II and their  
 2        pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
 3        enantiomers, diastereomers, N-oxides, polymorphs, or metabolites.




1        3. The compounds according to claim 1 having the structure of Formula III and their  
 2        pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
 3        enantiomers, diastereomers, N-oxides, polymorphs, or metabolites.




**Formula III**

1        4. The compounds according to claim 1 having the structure of Formula IV and their  
 2        pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
 3        enantiomers, diastereomers, N-oxides, polymorphs, or metabolites, wherein r is 1 to 4.



**Formula IV**

1 5. The compounds according to claim 1 having the structure of Formula V, and their  
 2 pharmaceutically acceptable salts, esters, enantiomers, N-oxides, or metabolites;  
 3 wherein s represents 1 to 2.

10 **Formula V**


1 6. A compound selected from the group consisting of  
 2 (2R,2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 3 cyclopentyl-2-phenyl acetamide (Compound 1);  
 4 (2R,2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 5 cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound 2);  
 6 (2R)-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 7 cyclopentyl-2-phenyl acetamide (Compound 3);  
 8 (2R)-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 9 cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound 4);  
 10 (2S)-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 11 cyclopentyl-2-phenyl acetamide (Compound 5);  
 12 (2S)-(1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 13 cyclopentyl-2-phenyl acetamide hydrochloride salt (Compound 6);  
 14 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-methoxy-2-  
 15 cyclopentyl-2-phenyl acetamide (Compound 7);  
 16 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 17 cycloheptyl-2-phenyl acetamide (Compound 8);  
 18 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 19 cyclobutyl-2-phenyl acetamide (Compound 9);  
 20 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 21 cyclobutyl-2-phenyl acetamide tartarate salt (Compound 10);  
 22 (2R) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-(3,3-  
 23 difluorocyclopentyl)-2-phenyl acetamide (Compound 11);  
 24 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 25 (3-fluorocyclopentyl)-2-phenyl acetamide (Compound 12);  
 26 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
 27 (3,3-difluorocyclopentyl)-2-phenyl acetamide (Compound 13);

28 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
29 (3,3-difluorocyclopentyl)-2-phenyl acetamide tartarate salt (Compound 14);  
30 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
31 2,2-diphenyl acetamide (Compound 15);  
32 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-  
33 2,2-diphenyl acetamide (Compound 16);  
34 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(aminomethyl)-yl]-2-hydroxy-2-  
35 cyclohexyl-2-phenyl acetamide (Compound 17) and  
36 (2R, 2S) (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-N-[3-azabicyclo[3.1.0]hexyl-6-(ylmethyl)-yl]-2-cyclopentyl-2-  
37 hydroxy-N-methyl-2-phenyl acetamide (Compound 18).

38 7. A pharmaceutical composition comprising a therapeutically effective amount of a  
39 compound as defined in claim 1, 2, 3, 4, 5 or 6 together with pharmaceutically  
40 acceptable carriers, excipients or diluents.

1 8. A method for treatment or prophylaxis of an animal or a human suffering from a  
2 disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein  
3 the disease or disorder is mediated through muscarinic receptors, comprising  
4 administering to said animal or human, a therapeutically effective amount of a  
5 compound having the structure of Formula I,

6



Formula I


12 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
13 enantiomers, diastereomers, N-oxides, polymorphs or metabolites, wherein

14 Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms, wherein the  
15 aryl or heteroaryl rings may be unsubstituted or substituted by one to three  
16 substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-  
17 C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>),  
18 unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino, amino carbonyl, or N-  
19 lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino carbonyl;

20 R<sub>1</sub> represents a hydrogen, hydroxy, hydroxy methyl, amino, alkoxy, carbamoyl or  
21 halogen;


22         $R_2$  represents alkyl,  $C_3$ - $C_7$  cycloalkyl ring, a  $C_3$ - $C_7$  cyclo alkenyl ring, an aryl,  
 23        heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms; the aryl, heteroaryl,  
 24        heterocyclic or a cycloalkyl ring may be unsubstituted or substituted by one to three  
 25        substituents independently selected from lower alkyl ( $C_1$ - $C_4$ ), lower perhalo alkyl ( $C_1$ -  
 26         $C_4$ ), cyano, hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy ( $C_1$ - $C_4$ ),  
 27        lower perhalo alkoxy ( $C_1$ - $C_4$ ), unsubstituted amino, N-lower alkyl ( $C_1$ - $C_4$ ) or -aryl  
 28        amino, amino carbonyl, or N-lower alkyl ( $C_1$ - $C_4$ ) or -aryl amino carbonyl;  
 29         $W$  represents  $(CH_2)_p$ , wherein  $p$  represents 0 to 1;  
 30         $X$  represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen  
 31        or ( $C_1$ - $6$ ) alkyl;  
 32         $Y$  represents  $CHR_5CO$  or  $(CH_2)_q$  wherein  $R_5$  represents hydrogen or methyl and  $q$   
 33        represents 0 to 4;  
 34         $Z$  represents oxygen, sulphur, or  $NR_{10}$ , wherein  $R_{10}$  represents hydrogen or  $C_1$ - $6$   
 35        alkyl;  
 36         $Q$  represents  $-(CH_2)_n-$ , wherein  $n$  represents 0 to 4,  $CHR_8$ , wherein  $R_8$  represents  
 37        H, OH,  $C_1$ - $6$ , alkyl,  $C_1$ - $6$  alkenyl,  $C_1$ - $6$  alkoxy, or  $Q$  represents  $CH_2CHR_9$ , wherein  $R_9$   
 38        represents H, OH, lower alkyl ( $C_1$ - $C_4$ ) or lower alkoxy ( $C_1$ - $C_4$ ); and  
 39         $R_6$  and  $R_7$  are independently selected from H,  $CH_3$ ,  $COOH$ ,  $CONH_2$ ,  $NH_2$ ,  
 40         $CH_2NH_2$ .

1        9. The method according to claim 8 for treatment or prophylaxis of an animal or a  
 2        human suffering from a disease or disorder of the respiratory, urinary and  
 3        gastrointestinal systems, wherein the disease or disorder is mediated through  
 4        muscarinic receptors, comprising administering to said animal or human, a  
 5        therapeutically effective amount of a compound having the structure of Formula II, its  
 6        pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
 7        enantiomers, diastereomers, N-oxides, polymorphs or metabolites.




Formula II

1 10. The method according to claim 8 for treatment or prophylaxis of an animal or a  
 2 human suffering from a disease or disorder of the respiratory, urinary and  
 3 gastrointestinal systems, wherein the disease or disorder is mediated through  
 4 muscarinic receptors, comprising administering to said animal or human, a  
 5 therapeutically effective amount of a compound having the structure of Formula III,  
 6 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
 7 enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites.



1 11. The method according to claim 8 for treatment or prophylaxis of an animal or a  
 2 human suffering from a disease or disorder of the respiratory, urinary and  
 3 gastrointestinal systems, wherein the disease or disorder is mediated through  
 4 muscarinic receptors, comprising administering to the said animal or human, a  
 5 therapeutically effective amount of a compound having the structure of Formula IV,  
 6 its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,  
 7 enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein  
 8 r is 1 to 4.




1 12. The method according to claim 8 for treatment or prophylaxis of an animal or a  
 2 human suffering from a disease or disorder of the respiratory, urinary and  
 3 gastrointestinal systems, wherein the disease or disorder is mediated through  
 4 muscarinic receptors, comprising administering to said animal or human, at least one  
 5 therapeutically effective amount of a compound having the structure of Formula V, its  
 6 pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters,

7 enantiomers, diastereomers, N-oxides, polymorphs or metabolites, wherein s  
 8 represents 1 to 2.

9

10



11

12

13

14

15

**Formula V**

1 13. The method according to claim 8 wherein the disease or disorder is urinary  
 2 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic  
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel  
 4 syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

1 14. The method according to claim 9 wherein the disease or disorder is urinary  
 2 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic  
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel  
 4 syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

1 15. The method according to claim 10 wherein the disease or disorder is urinary  
 2 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic  
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel  
 4 syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

1 16. The method according to claim 11 wherein the disease or disorder is urinary  
 2 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic  
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel  
 4 syndrome, obesity, diabetes or gastrointestinal hyperkinesis.


1 17. The method according to claim 12 wherein the disease or disorder is urinary  
 2 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic  
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel  
 4 syndrome, obesity, diabetes or gastrointestinal.

1 18. The method for treatment or prophylaxis of an animal or a human suffering from a  
 2 disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein  
 3 the disease or disorder is mediated through muscarinic receptors, comprising

4 administering to said animal or human, a therapeutically effective amount of the  
 5 pharmaceutical composition according to claim 7.

1 19. The method according to claim 18 wherein the disease or disorder urinary  
 2 incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic  
 3 obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel  
 4 syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

1 20. A method of preparing a compound of Formula I,



7 and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates,  
 8 esters, enantiomers, diastereomers, N-oxides, polymorphs or metabolites, wherein

9 Ar represents an aryl or a heteroaryl ring having 1-2 hetero atoms, wherein the  
 10 aryl or heteroaryl rings may be unsubstituted or substituted by one to three  
 11 substituents independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-  
 12 C<sub>4</sub>), cyano, hydroxy, nitro, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkoxy (C<sub>1</sub>-C<sub>4</sub>),  
 13 unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino, amino carbonyl, or N-  
 14 lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino carbonyl;

15 R<sub>1</sub> represents a hydrogen, hydroxy, hydroxy methyl, amino, alkoxy, carbamoyl or  
 16 halogen;

17 R<sub>2</sub> represents alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl ring, a C<sub>3</sub>-C<sub>7</sub> cyclo alkenyl ring, an aryl,  
 18 heterocyclic or a heteroaryl ring having 1 to 2 hetero atoms selected from a group  
 19 consisting of oxygen, sulphur and nitrogen atoms; the aryl, heteroaryl, heterocyclic or  
 20 a cycloalkyl ring may be unsubstituted or substituted by one to three substituents  
 21 independently selected from lower alkyl (C<sub>1</sub>-C<sub>4</sub>), lower perhalo alkyl (C<sub>1</sub>-C<sub>4</sub>), cyano,  
 22 hydroxy, nitro, lower alkoxy carbonyl, halogen, lower alkoxy (C<sub>1</sub>-C<sub>4</sub>), lower perhalo  
 23 alkoxy (C<sub>1</sub>-C<sub>4</sub>), unsubstituted amino, N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino, amino  
 24 carbonyl, or N-lower alkyl (C<sub>1</sub>-C<sub>4</sub>) or -aryl amino carbonyl;

25 W represents (CH<sub>2</sub>)<sub>p</sub>, wherein p represents 0 to 1;

26 X represents an oxygen, sulphur, -NR or no atom, wherein R represents hydrogen  
 27 or (C<sub>1-6</sub>) alkyl;


28 Y represents  $\text{CHR}_5\text{CO}$  or  $(\text{CH}_2)_q$  wherein  $\text{R}_5$  represents hydrogen or methyl and q  
29 represents 0 to 4;

30 Z represents oxygen, sulphur, NR<sub>10</sub>, wherein R<sub>10</sub> represents hydrogen, C<sub>1-6</sub> alkyl;  
31 Q represents (CH<sub>2</sub>)<sub>n</sub> (wherein n represents 0 to 4), CHR<sub>8</sub> (wherein R<sub>8</sub> represents  
32 H, OH, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkenyl, C<sub>1-6</sub> alkoxy) or CH<sub>2</sub>CHR<sub>9</sub> (wherein R<sub>9</sub> represents H,  
33 OH, lower alkyl (C<sub>1-C</sub>4) or lower alkoxy (C<sub>1-C</sub>4)); and


34 R<sub>6</sub> and R<sub>7</sub> are independently selected from H, CH<sub>3</sub>, COOH, CONH<sub>2</sub>, NH<sub>2</sub>,  
35 CH<sub>2</sub>NH<sub>2</sub>;

36 said method comprising:

37 (a) reacting a compound of Formula VII with a compound of Formula VI




### Formula VII




### Formula VI

44 to give a protected compound of Formula VIII wherein Ar, R<sub>1</sub>, R<sub>2</sub>, W, X, Y, Z, and Q  
45 are as defined, and P is a protecting group for an amino group



### Formula VIII

48 (b) deprotecting the compound of Formula VIII in the presence of a deprotecting  
49 agent to give compound of Formula I wherein Ar, R<sub>1</sub>, R<sub>2</sub>, W, X, Y, Z, and Q are as  
50 defined, H R<sub>2</sub>



### Formula I

1 21. The method of claim 20, wherein P is any protecting group for an amino group and is  
2 selected from the group consisting of benzyl and t-butyloxycarbonyl groups.

- 1    22. The method of claim 20, wherein the reaction of a compound of Formula VI with a
- 2       compound of Formula VII to give a compound of Formula VIII is carried out in the
- 3       presence of a condensing agent which is selected from the group consisting of 1-(3-
- 4       dimethyl amino propyl)-3-ethyl carbodiimide hydrochloride (EDC) and 1,8-
- 5       diazabicyclo [5.4.0]undec-7-ene (DBU).
- 1    23. The method of claim 20, wherein the reaction of a compound of Formula VI with a
- 2       compound of Formula VII is carried out in a suitable polar aprotic solvent selected
- 3       from the group consisting of N,N-dimethylformamide, dimethyl sulfoxide, toluene,
- 4       and xylene.
- 1    24. The method of claim 20, wherein the reaction of compound of Formula VI with a
- 2       compound of Formula VII is carried out at 0-140°C.
- 1    25. The method of claim 20, wherein the deprotection of a compound of Formula VIII is
- 2       carried out with a deprotecting agent which is selected from the group consisting of
- 3       palladium on carbon, trifluoroacetic acid (TFA) and hydrochloric acid.
- 1    26. The method of claim 20, wherein the deprotection of a compound of Formula VIII to
- 2       give a compound of Formula I is carried out in a suitable organic solvent selected
- 3       from the group consisting of methanol, ethanol, tetrahydrofuran and acetonitrile.